← All trials
NCT05358691
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 30, 2023
- Primary completion
- Dec 1, 2027
- Completion date
- Jun 1, 2028
- First posted
- May 3, 2022
- Last posted
- Nov 4, 2022
- Enrollment
- 24
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Rutgers UniversityLead sponsor
- Rutgers UniversityOverall official - principal investigator
- Rutgers UniversityReponsible party - principal investigator
- Adlai Nortye Biopharma Co., Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.